Premium Nahrungsergänzungsmittel | artgerecht

Retatrutide – Mechanism, Uses & Clinical Trials

Retatrutide is an investigational drug for obesity and type 2 diabetes that simultaneously activates three gut hormone receptors: GLP-1, GIP, and glucagon.

Regular tips about health Regular tips about health

Things worth knowing about "Retatrutide"

Retatrutide is an investigational drug for obesity and type 2 diabetes that simultaneously activates three gut hormone receptors: GLP-1, GIP, and glucagon.

What is Retatrutide?

Retatrutide is an innovative investigational compound developed by Eli Lilly and Company. It belongs to the class of triple agonists, meaning it simultaneously activates three distinct hormone receptors: the GLP-1 receptor (glucagon-like peptide-1), the GIP receptor (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This triple mechanism sets Retatrutide apart from already approved medications such as semaglutide (GLP-1 agonist) or tirzepatide (dual GLP-1/GIP agonist).

Mechanism of Action

Retatrutide works by simultaneously targeting three hormonal pathways:

GLP-1 receptor agonism: Stimulates insulin secretion, suppresses appetite, and slows gastric emptying, leading to reduced food intake and improved blood sugar control.
GIP receptor agonism: Enhances insulin sensitivity and supports fat metabolism, contributing to weight loss and better glycemic regulation.
Glucagon receptor agonism: Increases energy expenditure and promotes fat breakdown in the liver, which may be particularly beneficial for conditions such as non-alcoholic fatty liver disease (NAFLD/NASH).

The synergistic action of these three mechanisms has demonstrated remarkable effects on body weight reduction and metabolic control in clinical trials.

Medical Indications

Retatrutide is currently being evaluated in Phase III clinical trials for the following conditions:

Obesity: Phase II data showed a mean weight reduction of up to 24% of baseline body weight over 48 weeks -- an unprecedented result for a drug in this class.
Type 2 diabetes mellitus: The combination of insulin stimulation and significant weight loss could substantially improve long-term glycemic management.
Non-alcoholic fatty liver disease (NAFLD/NASH): The glucagon-mediated promotion of hepatic fat metabolism positions Retatrutide as a potential treatment option for this condition.
Cardiovascular risk reduction: Improved metabolic parameters and sustained weight loss are associated with lower cardiovascular risk.

Dosage and Administration

Retatrutide is administered as a once-weekly subcutaneous injection, consistent with other GLP-1-based therapies. Clinical studies have tested doses ranging from approximately 1 mg to 12 mg per week. The final approved dosing regimen has not yet been established, as the compound is still under regulatory review and late-stage development.

Side Effects

Based on Phase II clinical trial data, Retatrutide shows a side effect profile broadly comparable to other incretin-based therapies:

Common: Nausea, vomiting, diarrhea, constipation -- especially during dose escalation at the start of treatment.
Occasional: Decreased appetite, bloating, belching.
Less common: Increased resting heart rate (attributable to the glucagon component), and potential risk of gallbladder-related issues.

Because the glucagon receptor component can elevate blood glucose levels, careful monitoring is particularly important when Retatrutide is used alongside other antidiabetic medications.

Current Development Status

As of the latest available information, Retatrutide is in Phase III clinical trials. It has not yet received regulatory approval from the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA). Pending successful trial outcomes, market availability is anticipated in the latter half of the 2020s.

References

Jastreboff AM et al. - Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine, 2023; 389(6): 514-526.
Eli Lilly and Company - Retatrutide Clinical Development Program. Official press releases and study data, 2023-2024.
World Health Organization (WHO) - Obesity and Overweight Fact Sheet. Geneva, 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.